+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 70Years
All Genders
ID06882122

Study of Atogepant 60 mg Daily for 3 Months in Adults with High-Frequency Episodic Migraine Evaluating Brain and Biochemical Changes to Understand Treatment Effects

Led by IRCCS National Neurological Institute "C. Mondino" Foundation · Updated on 2025-03-18

30

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of atogepant, a CGRP receptor antagonist, on patients with high-frequency episodic migraine who experience 8 to 14 migraine days per month. The study aims to understand how atogepant changes brain function and biochemical markers related to migraine, helping to identify predictors of treatment response and potential alternative therapies for those who do not benefit from it. This research focuses on the neurophysiological and biomolecular mechanisms involved in migraine and the impact of atogepant on these pathways. Participants will take atogepant 60 mg daily for three months. The study involves detailed neurofunctional assessments, including High-Density EEG, nociceptive reflexes, and visual evoked potentials, as well as biochemical tests measuring gene expression of endocannabinoid enzymes, plasma levels of CGRP and PACAP, and specific migraine-related microRNAs. These evaluations occur at the start and end of the treatment period to compare changes over time. During the study, patients will undergo clinical evaluations, biochemical sampling between 9 and 11 a.m. to avoid circadian influence, and various neurophysiological recordings. Researchers will track outcomes such as the temporal summation threshold of the RIII reflex and gene expression of MAGL, among others. The study will also monitor safety and treatment effects through a comprehensive set of biochemical and neurofunctional markers, with a total participation duration of three months under close observation.

CONDITIONS

Brief Title

Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine

Research Team

F

Francescantonio Cammarota, MD

C

Cinzia Fattore

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here